Recently, our group has shown that in vitro exposure to pevonedistat downregulated activation of proximal T-cell receptor (TCR) signaling, accompanied by suppression of NF-κB-regulated genes and IL-2 signaling in T cells derived from patients with chronic lymphocytic leukemia (CLL) [24]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.